



LKT Laboratories, Inc.

**AZD-8055**

Phone: 888-558-5227

651-644-8424

Fax: 888-558-7329

Email: [getinfo@lctlabs.com](mailto:getinfo@lctlabs.com)

Web: [lctlabs.com](http://lctlabs.com)

## Product Information

Product ID A9914

CAS No. 1009298-09-2

Chemical Name

Synonym AZD-8055

Formula  $C_{25}H_{31}N_5O_4$

Formula Wt. 465.55

Melting Point


Purity  $\geq 98\%$

Solubility DMSO 50 mg/mL warmed (107.4 mM)  
Ethanol 3 mg/mL (6.44 mM)  
Water Insoluble

Store Temp  $-20^{\circ}\text{C}$

Ship Temp Ambient

**Description** AZD-8055 is an ATP-competitive mTORC1/2 inhibitor that exhibits immunosuppressive and anticancer chemotherapeutic activities. AZD-8055 promotes antibody class switching in B cells at low doses and decreases B cell proliferation and differentiation at high doses. In vivo, this compound suppresses CC4+ and CD8+ T cell proliferation, increasing survival among MHC-mismatched heart transplant recipients. In vitro, AZD-8055 decreases viability of brain tumor cells; in vivo, it inhibits tumor growth.



## Pricing and Availability

*Bulk quantities available upon request*

Product ID	Size	List Price
A9914	5 mg	\$72.50
A9914	25 mg	\$233.40
A9914	50 mg	\$361.60

**References** Limon JJ, So L, Jellbauer S, et al. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):E5076-85. PMID: 25385646.

Luchman HA, Stechishin OD, Nguyen SA, et al. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival. Clin Cancer Res. 2014 Nov 15;20(22):5756-67. PMID: 25316808.

Rosborough BR, Raïch-Regué D, Liu Q, et al. Adenosine triphosphate-competitive mTOR inhibitors: a new class of immunosuppressive agents that inhibit allograft rejection. Am J Transplant. 2014 Sep;14(9):2173-80. PMID: 25307040.

**Caution:** This product is intended for laboratory and research use only. It is not for human or drug use.